trial · primary record
Cemsidomide
Multiple Myeloma
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 100 |
| Primary completion | 2030-03 |
| Primary endpoint | Overall response rate (ORR) per International Myeloma Working Group (IMWG) Response Criteria by an Independent Review Committee (IRC) |
| Registry ID | NCT07284758 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-30T14:41:36.022Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07284758
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Cemsidomide · compound